In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may not be safe.

Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

As a diabetes medication, GLP-1s are able to treat insulin resistance, something that many people with PCOS deal with. “It’s ...

Here’s some of our top analysis to help you make sense of it all. Accountable care organizations and healthcare providers are ...

I n a world where seeking help to manage weight is still frowned upon and deemed as “lazy,” many are turning to common tools ...